REGULAR CONTENT
Final ID
503
Type
Original Scientific Research-Oral or Pos
Authors
G Kim1, J Won1, M Kim1, S Park1, D Lee1, K Han1, K Joon Ho1, J Koo2
Institutions
1Severance Hospital, Yonsei University College of Medicine, Seoul, Seodaemun-gu, 2Gwangmyung Sungae Hostpial, Gwangmyung, AK
Purpose
Therasphere (Yttrium-90 loaded glass microsphere) was first introduced in Korea on November 2015. This study presents early outcomes of radioembolization using Therasphere for the treatment of hepatocellular carcinoma (HCC) secondary to hepatitis B virus (HBV) in Korea, where is a HBV endemic area.
Materials & Methods
From November 2015 to June 2016, 25 patients underwent radioembolization using Therasphere for the treatment of HCC in our institution. Among them, seventeen patients with HBV-related liver cirrhosis were included. We reviewed their electronic medical records and images to evaluate demographic factors, hepatic function, tumor characteristics, factors associated with radioembolization, and treatment response.
Results
The patients consisted of thirteen men and four women, and their mean age was 61.5 years (range, 41-85). Child-Pugh classification was A in the all patients. Barcelona Clinic Liver Cancer stage was A in one, B in eight, and C in eight. Mean tumor size was 68.2mm (range, 38-100) and six patients had lobar or segmental portal vein invasion. Five patients underwent combined chemoembolization for the small nodule(s) of contralateral lobe during planning angiography. No patient showed deterioration of hepatic function in one month after treatment. Mean follow-up period was 123 (range, 49-192) days, the target lesions showed complete response in six, partial response in six, stable disease in one, and progressive disease in four patients. The complete response group includes two patients with portal vein invasion. Local control rate was 76.5%.
Conclusions
Radioembolization using Therasphere is an effective treatment modality for the treatment of advanced HCC secondary to HBV.
Final ID
503
Type
Original Scientific Research-Oral or Pos
Authors
G Kim1, J Won1, M Kim1, S Park1, D Lee1, K Han1, K Joon Ho1, J Koo2
Institutions
1Severance Hospital, Yonsei University College of Medicine, Seoul, Seodaemun-gu, 2Gwangmyung Sungae Hostpial, Gwangmyung, AK
Purpose
Therasphere (Yttrium-90 loaded glass microsphere) was first introduced in Korea on November 2015. This study presents early outcomes of radioembolization using Therasphere for the treatment of hepatocellular carcinoma (HCC) secondary to hepatitis B virus (HBV) in Korea, where is a HBV endemic area.
Materials & Methods
From November 2015 to June 2016, 25 patients underwent radioembolization using Therasphere for the treatment of HCC in our institution. Among them, seventeen patients with HBV-related liver cirrhosis were included. We reviewed their electronic medical records and images to evaluate demographic factors, hepatic function, tumor characteristics, factors associated with radioembolization, and treatment response.
Results
The patients consisted of thirteen men and four women, and their mean age was 61.5 years (range, 41-85). Child-Pugh classification was A in the all patients. Barcelona Clinic Liver Cancer stage was A in one, B in eight, and C in eight. Mean tumor size was 68.2mm (range, 38-100) and six patients had lobar or segmental portal vein invasion. Five patients underwent combined chemoembolization for the small nodule(s) of contralateral lobe during planning angiography. No patient showed deterioration of hepatic function in one month after treatment. Mean follow-up period was 123 (range, 49-192) days, the target lesions showed complete response in six, partial response in six, stable disease in one, and progressive disease in four patients. The complete response group includes two patients with portal vein invasion. Local control rate was 76.5%.
Conclusions
Radioembolization using Therasphere is an effective treatment modality for the treatment of advanced HCC secondary to HBV.